Parathyroid-Specific Deletion of Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion

English version České info

Klotho acts as a co-receptor for and dictates tissue specificity of circulating FGF23. FGF23 inhibits PTH secretion, and reduced Klotho abundance is considered a pathogenic factor in renal secondary hyperparathyroidism. To dissect the role of parathyroid gland resident Klotho in health and disease, we generated mice with a parathyroid-specific Klotho deletion (PTH-KL^−/−). PTH-KL^−/− mice had a normal gross phenotype and survival; normal serum PTH and calcium; unaltered expression of the PTH gene in parathyroid tissue; and preserved PTH response and sensitivity to acute changes in serum calcium. Their PTH response to intravenous FGF23 delivery or renal failure did not differ compared to their wild-type littermates despite disrupted FGF23-induced activation of the MAPK/ERK pathway. Importantly, calcineurin-NFAT signaling, defined by increased MCIP1 level and nuclear localization of NFATC2, was constitutively activated in PTH-KL^−/− mice. Treatment with the calcineurin-inhibitor cyclosporine A abolished FGF23-mediated PTH suppression in PTH-KL^−/− mice whereas wild-type mice remained responsive. Similar results were observed in thyro-parathyroid explants ex vivo. Collectively, we present genetic and functional evidence for a novel, Klotho-independent, calcineurin-mediated FGF23 signaling pathway in parathyroid glands that mediates suppression of PTH. The presence of Klotho-independent FGF23 effects in a Klotho-expressing target organ represents a paradigm shift in the conceptualization of FGF23 endocrine action.

Vyšlo v časopise: Parathyroid-Specific Deletion of Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion. PLoS Genet 9(12): e32767. doi:10.1371/journal.pgen.1003975
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003975

Souhrn

Zdroje

1. PottsJT (2005) Parathyroid hormone: past and present. J Endocrinol 187: 311–325.

2. ChenRA, GoodmanWG (2004) Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 286: F1005–1011.

3. UrakawaI, YamazakiY, ShimadaT, IijimaK, HasegawaH, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770–774.

4. Kuro-oM, MatsumuraY, AizawaH, KawaguchiH, SugaT, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45–51.

5. KrajisnikT, BjorklundP, MarsellR, LjunggrenO, AkerstromG, et al. (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195: 125–131.

6. Ben-DovIZ, GalitzerH, Lavi-MoshayoffV, GoetzR, Kuro-oM, et al. (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003–4008.

7. ImuraA, TsujiY, MurataM, MaedaR, KubotaK, et al. (2007) alpha-Klotho as a regulator of calcium homeostasis. Science 316: 1615–1618.

8. MartusevicieneG, Hofman-BangJ, ClausenT, OlgaardK, LewinE (2011) The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int 79: 742–748.

9. GalitzerH, Ben-DovIZ, SilverJ, Naveh-ManyT (2010) Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77: 211–218.

10. CanalejoR, CanalejoA, Martinez-MorenoJM, Rodriguez-OrtizME, EstepaJC, et al. (2010) FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21: 1125–1135.

11. KrajisnikT, OlausonH, MirzaMA, HellmanP, AkerstromG, et al. (2010) Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78: 1024–1032.

12. KomabaH, GotoS, FujiiH, HamadaY, KobayashiA, et al. (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77: 232–238.

13. LibuttiSK, CrabtreeJS, LorangD, BurnsAL, MazzantiC, et al. (2003) Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 63: 8022–8028.

14. ImanishiY, HallC, SabloskyM, BrownEM, ArnoldA (2002) A new method for in vivo analysis of parathyroid hormone-calcium set point in mice. J Bone Miner Res 17: 1656–1661.

15. JiaT, OlausonH, LindbergK, AminR, EdvardssonK, et al. (2013) A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol 14: 116.

16. FaulC, AmaralAP, OskoueiB, HuMC, SloanA, et al. (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393–4408.

17. ByrdVM, KilkennyDM, DikovMM, ReichMB, RocheleauJV, et al. (2003) Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway. Immunol Cell Biol 81: 440–450.

18. GoetzR, MohammadiM (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14: 166–180.

19. SannaB, BrandtEB, KaiserRA, PflugerP, WittSA, et al. (2006) Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A 103: 7327–7332.

20. RitterCS, BrownAJ (2011) Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol 46: 63–66.

21. BellO, GabermanE, KilavR, LeviR, CoxKB, et al. (2005) The protein phosphatase calcineurin determines basal parathyroid hormone gene expression. Mol Endocrinol 19: 516–526.

22. MirzaMA, HansenT, JohanssonL, AhlstromH, LarssonA, et al. (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24: 3125–3131.

23. MirzaMA, LarssonA, LindL, LarssonTE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385–390.

24. MirzaMA, LarssonA, MelhusH, LindL, LarssonTE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207 (2) 546–51.

25. GutierrezOM, JanuzziJL, IsakovaT, LaliberteK, SmithK, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545–2552.

26. GutierrezOM, MannstadtM, IsakovaT, Rauh-HainJA, TamezH, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584–592.

27. FliserD, KolleritsB, NeyerU, AnkerstDP, LhottaK, et al. (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600–2608.

28. LundbergS, QureshiAR, OlivecronaS, GunnarssonI, JacobsonSH, et al. (2012) FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 7: 727–734.

29. LarssonT, NisbethU, LjunggrenO, JuppnerH, JonssonKB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272–2279.

30. Lavi-MoshayoffV, WassermanG, MeirT, SilverJ, Naveh-ManyT (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882–889.

31. WolfM (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427–1435.

32. NechamaM, UchidaT, Mor Yosef-LeviI, SilverJ, Naveh-ManyT (2009) The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest 119: 3102–3114.

33. OlausonH, LindbergK, AminR, JiaT, WernersonA, et al. (2012) Targeted deletion of klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 23: 1641–1651.

34. HarrisonBC, RobertsCR, HoodDB, SweeneyM, GouldJM, et al. (2004) The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 24: 10636–10649.

35. GoetzR, NakadaY, HuMC, KurosuH, WangL, et al. (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107: 407–412.

36. GoetzR, BeenkenA, IbrahimiOA, KalininaJ, OlsenSK, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417–3428.